Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Returning investor PPD co-led a $40m round for the remote clinical trials service, while Novartis, Amgen, Sanofi and Alphabet also doubled down on their commitments.

The patient communication app developer took its total funding past the $30m mark with a round co-led by Google's Gradient Ventures fund.

Tsinghua-backed Rokae is working on lightweight robots with a wide range of applications and has now raised $43.5m altogether.

GI Windows Medical plans to put the $16.4m from the Johnson & Johnson Innovation – JJDC-backed round into clinical validation of its anastomotic endoscopy device.

Eli Lilly and WuXi Biologics-backed biologics developer Inhibrx floated at the midpoint of its range having previously raised $135m in debt and equity financing.

Dizal, co-founded by AstraZeneca three years ago to develop therapies for a broad range of diseases, pulled in $100m through a round led by Lilly Asia Ventures.

Reliance Industries has paid $82.6m for a majority stake in NetMeds, an online pharmacy that had raised $99m from backers including Daun Penh Cambodia Group and Sistema.

Sequoia Capital China led a $72.3m round for the drug developer, which counts Xiamen Air and Pien Tze Huang-among its early investors.

Johnson & Johnson, Takeda, Novartis and Bukwang Pharmaceutical all backed the first round disclosed by oncology drug developer Immpact Bio USA.